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Abstract Galactose epimerase deficiency is an inborn error
of metabolism due to uridine diphosphate-galactose-40-
epimerase (GALE) deficiency. We report the clinical
presentation, genetic and biochemical studies in two
siblings with generalized GALE deficiency.
Patient 1: The first child was born with a dysmorphic
syndrome. Failure to thrive was noticed during the first
year. Episodes of heart failure due to dilated cardiomyopa-
thy, followed by liver failure, occurred between 12 and 42
months. The finding of a serum transferrin isoelectrofocus-
ing (IEF) type 1 pattern led to the suspicion of a congenital
disorder of glycosylation (CDG). Follow-up disclosed
psychomotor disability, deafness, and nuclear cataracts.
Patient 2: The sibling of patient 1 was born with short
limbs and hip dysplasia. She is deceased in the neonatal
period due to intraventricular hemorrhage in the context of
liver failure. Investigation disclosed galactosuria and
normal transferrin glycosylation.
Next-generation sequence panel analysis for CDG
syndrome revealed the previously reported c.280G>A (p.
[V94M]) homozygous mutation in the GALE gene. Enzy-
matic studies in erythrocytes (patient 1) and fibroblasts
(patients 1 and 2) revealed markedly reduced GALE
activity confirming generalized GALE deficiency. This
report describes the fourth family with generalized GALE
deficiency, expanding the clinical spectrum of this disorder,
since major cardiac involvement has not been reported
before.
Introduction
Uridine diphosphate-galactose-40-epimerase (GALE) defi-
ciency is a very rare disease of galactose metabolism and
the Leloir pathway. This enzyme catalyzes the conversion
of uridine diphosphate galactose (UDP-Gal) to uridine
diphosphate glucose (UDP-Glc) (Segal and Berry 1995),
as well as the reverse reaction when other sources of UDP-
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Gal are scarce. GALE also plays a role in the interconver-
sion of uridine diphosphate-N-acetylgalactosamine and
uridine diphosphate-N-acetylglucosamine (Wohlers et al.
1999). These uridine diphosphate sugars are essential for
the glycosylation of proteins and lipids, and their restriction
can lead to the production and accumulation of hypoga-
lactosylated glycans, which are suggested to contribute to
the long-term complications in galactosemia (Charlwood
et al. 1998). Thus, galactosemia is a cause of secondary
hypoglycosylation (Sturiale et al. 2005).
The clinical severity of GALE deficiency ranges from
benign to potentially lethal, depending on the degree of
reduction of GALE activity and the tissues affected. The
first reported case (Gitzelmann 1972) was described as a
benign condition, a “peripheral” form of the disease, in
which the GALE impairment was restricted to the circulat-
ing blood cells. In 1981, (Holton et al. 1981) described the
first case of “generalized” GALE deficiency, a patient with
a severe clinical presentation, similar to classic galacto-
semia, with reduced GALE activity in both circulating red
blood cells and fibroblasts. As pointed out by Openo,
GALE deficiency is not a binary condition but a continuum
disorder (Openo et al. 2006). There are three forms
currently recognized: (1) a peripheral form, with decreased
enzyme activity in red blood cells and leucocytes, with
normal or near normal levels in all other tested tissues; (2)
an intermediate form, with decreased enzyme activity in
circulating blood cells, and less than 50% in all other
tissues tested; and (3) a generalized form, with a profound
generalized decrease of enzyme activity (Fridovich-Keil
2013). The peripheral form is reported to occur with a
frequency of 1:6,700 to 1:60,000 depending on the ethnic
background (Alano et al. 1998), while the severe
generalized form is extremely rare (Holton et al. 2000)
with only three families (six patients) described (Holton
et al. 1981; Sardharwalla et al. 1988; Walter et al. 1999;
Sarkar et al. 2010).
The present report is on two sisters with different
phenotypes, expanding the clinical spectrum of generalized
GALE deficiency, and reviews the literature on this GALE
deficiency form.
Patient Reports
Patient 1 (Fig. 1)
This first female child of non-consanguineous Caucasian
parents was born after a full-term pregnancy. The mother
was treated for hypothyroidism. The biochemical and
ultrasound screening showed a high risk for trisomy 21,
but there was a normal karyotype on amniocentesis.
The newborn was admitted to the NICU during the first
week due to a dysmorphic syndrome: relative macro-
cephaly, hypertelorism, micrognathia, finger contractures,
short limbs, hip dislocation, positional talipes, and ligament
laxity. During the first year of life, failure to thrive,
hypotonia, and psychomotor disability were noticed. Cere-
bral ultrasound and electromyography were normal.
At 12 and 16 months old, she was hospitalized in the
PICU with heart failure due to dilated cardiomyopathy,
followed by hepatomegaly and acute liver failure. She
recovered under supportive therapy and was discharged on
diuretic medication. Infectious etiologies were excluded,
and pituitary hormones and brain MRI were normal.
At the ages of 18, 41, 42, and 43 months, she was
hospitalized with heart decompensation that responded well
to anticongestive heart therapy.
Results of other investigations included persistently
raised serum aminotransferases (3–4 times the upper limit
of normal) until 4 years old, negative urinary-reducing
sugars, and unspecific alterations in urinary organic acids,
plasma amino acids, and acylcarnitine profile. A diagnosis
of congenital disorder of glycosylation (CDG) was
hypothesized based on a high serum level of carbohy-
drate-deficient transferrin (CDT) on several occasions
(3–10.2%; reference range <2.6%). Serum transferrin
isoelectrofocusing (IEF) showed a type 1 pattern, and the
fibroblast LLO (lipid-linked oligosaccharides) profile was
normal (small mannose 2 glycan accumulation). Phospho-
mannomutase and phosphomannose isomerase activities in
fibroblasts were normal, and there were no mutations in
ALG2, DPM3, DK1, and SRD5A3 genes.
During follow-up (Fig. 1a–c), on regular diet and till the
present age of 12 years, the dysmorphic features attenuated.
She showed a short stature (height, 2.9 SD; weight,
0.17 SD), global developmental disability with slow
acquisitions (15–19 months at 10 years old on Vineland
Adaptive Behavior Scales) (Sparrow et al. 2005), a
behavior disorder controlled with risperidone, sensorineural
hearing loss detected at 3 years old, and bilateral nuclear
cataracts diagnosed and surgically treated at 8 years old.
Cardiac function normalized under furosemide and spiro-
nolactone and dilated cardiomyopathy has progressively
improved. The medication is being gradually withdrawn.
Patient 2 (Fig. 2)
After the birth of a healthy male sibling, the third child of
the same couple, a female, was born following an
uneventful term pregnancy. She presented relative macro-
cephaly, short limbs, and bilateral hip dislocation and was
discharged under breastfeeding. At the 8th day of life, she
was admitted to the local hospital for poor feeding and
lethargy. Hypotonia, hypothermia, and hypoglycemia were
noticed. After initial stabilization and because of persistent
depressed consciousness, she was transferred to the PICU.
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On admission, encephalopathy, jaundice, and hepatomegaly
were observed. Acute liver failure was confirmed, with
severe coagulopathy, thrombocytopenia, and anemia,
requiring multiple transfusions. Death occurred on the
17th day, with severe intraventricular hemorrhage, despite
a lactose-free regimen.
Investigations revealed positive urine-reducing sugars
(20 g/L) without glycosuria; generalized hyperaminoacidu-
ria; high plasma glycine, glutamine, alanine, tyrosine, and
phenylalanine, and unspecific abnormalities in urinary
organic acids. Acylcarnitine profile on Guthrie card,
pituitary hormones, and serum transferrin IEF were normal.
Viral infections, neonatal hemochromatosis, and hemopha-
gocytic lymphohistiocytosis were excluded. Autopsy
showed a small liver with massive hepatic necrosis,
cholestasis, large kidneys with intratubular renal calcifica-
tions, hepatopancreatic siderosis, and subarachnoid and
intraventricular hemorrhages. Postmortem mitochondrial
respiratory chain functional studies showed deficits of
complexes I, II, IV, and V in the liver and heart and
normal activities in the muscle, with normal results for
mtDNA copy number, mtDNA genome, and DGUOK gene
analysis.
Gene panel using massive parallel sequencing (target
capture CDGv1, NimbleGen) revealed the previously
reported homozygous c.[280G>A] p.[V94M] mutation in
GALE in both sisters, leading to the diagnosis of GALE
deficiency (MIM 230350). The parents are heterozygous
for the same mutation. GALE activity was markedly
reduced in erythrocytes of patient 1 [0.6 mmol/(h.gHb);
reference range 5.7–22.1] and also in fibroblasts of both
patients 1 and 2 confirming generalized GALE deficiency.
In patient 1, erythrocyte galactose 1-phosphate and urinary
polyols chromatography were normal on an unrestricted
diet.
Table 1 shows clinical, biochemical, and genetic char-
acteristics of the present patients and the reported ones.
Discussion
Generalized GALE deficiency has only been reported in
six patients from three families (Table 1). In one of the
patients previously described (case 8), GALE was only
assayed in red cells, and no genetic studies were under-
taken therefore making it difficult to confirm the diagnosis
of generalized GALE deficiency, besides the severe
clinical presentation described (Sarkar et al. 2010). The
other five patients belong to two highly consanguineous
families. This constitutes a difficulty in attributing some
features to generalized GALE deficiency with certainty.
Although the parents of patients 1 and 2 affirmed to be
non-consanguineous, a farthermost possibility of a shared
ancestry couldn’t be ruled out. Nevertheless, excluding
cardiac involvement, all of the other features described can
be attributed to GALE deficiency, according to the
previous published descriptions of this disease. A majority
of patients showed hepatic symptoms (7/8), hypotonia (5/
8), and, during follow-up, short stature (7/7), developmen-
tal disability (7/7), and sensorineural hearing loss (4/7).
Symptoms present in a minority of patients were micro-
gnathia, flexion deformities of the fingers, dislocatable
hip/hip dysplasia, and positional talipes equinovarus.
Galactosemia was not considered in patient 1, since liver
involvement happened outside the neonatal period, reduc-
ing sugars were negative, recovery was almost complete
under a normal diet, and cataracts appeared only at 8 years.
Thus, the lack of the classic newborn severe liver
presentation, which emerged in the younger sister, con-
tributed to the diagnostic delay in this family. This
Fig. 1 (a–c) Case 1, older sibling with generalized GALE deficiency
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different severity in clinical presentation overlaps the
description made by Walter et al. (1999), in which the
index cases for each family presented earlier with severe
clinical illness similar to that seen in classic galactosemia,
with poor feeding, weight loss, liver disease, and tubul-
opathy, while the other members of those families (cases
4, 6, and 7 of Table 1), who had the same homozygous
mutation, were diagnosed before noticeable disease has
developed. Another curious fact is that the older sibling
(case 1) didn’t show any sign of milk intolerance until
date. The available knowledge about GALE deficiency is
still insufficient to explain these differences in clinical
presentation. In patient 1, the multisystem involvement
with dysmorphism, cardiomyopathy, and developmental
disability associated with high levels of serum CDT, and a
type 1 pattern on IEF led to the suspicion of a CDG, which
remained “type X,” since no enzyme deficiency or
mutation was found. Galactosemia type 1 and 3 are known
causes of secondary hypoglycosylation of proteins and
lipids (Charlwood et al. 1998, Sturiale et al. 2005).
Hypertrophic and dilated cardiomyopathy is a known
feature of some CDG, most commonly in a multisystem
presentation, early in life, although late-onset and non-
syndromic cases have also been reported (Lefeber et al.
2011). Dilated cardiomyopathy was the main clinical
feature in patient 1 for some years, but it was absent in
her younger sister. To our knowledge, this is the first
generalized GALE-deficient patient with dilated cardio-
myopathy.
The c.[280G>A] (p.[V94M]) mutation in the GALE
gene has been found in a homozygous form in all of the
patients tested with the severe phenotype (Table 1). Other
mutations are associated with the intermediate or asymp-
tomatic phenotype (Openo et al. 2006; Wasilenko et al.
2005).
A peculiar feature in patient 1 was the absence of
accumulation of galactose metabolism products [total
galactose and galactose-1-phosphate (Gal-1-P)]. A similar
situation was already described in patients with intermedi-
ate and peripheral GALE deficiency (Openo et al. 2006).
Galactose is an essential constituent of the glycosphin-
golipids, required for brain growth and development. The
galactose metabolism includes the Leloir and the pyrophos-
phorylase pathways, and epimerase is a key enzyme in
both. In the Leloir pathway, the conversion of Gal-1-P to
glucose-1-phosphate (Glc-1-P) is made by the enzyme
galactose-1-phosphate uridyltransferase. In this reaction,
UDP-GIc is converted to UDP-Gal. Epimerase regenerates
UDP-Glc from UDP-Gal, allowing the maintenance of this
cycle. The pyrophosphorylase constitutes an alternative
pathway, which allows the synthesis of UDP-Gal in its
direct route in patients with transferase deficiency or, in its
reversal route, when galactose intake is restricted (Holton
et al. 1981). In epimerase deficiency, the patients are unable
to synthetize UDP-Gal by this way and depend on
exogenous galactose for its synthesis (Holton et al. 1981).
Henderson et al. (1983) suggested that, in galactose
epimerase deficient patients, a small amount of adminis-
tered galactose will be metabolized via the Leloir pathway
to produce UDP-Gal. UDP-Glc cannot be regenerated from
UDP-Gal but could be formed from UTP and Glc-1-P and
used as a cofactor in the maintenance of transferase activity.
Thus, under these circumstances, galactose and Gal-1-P
will not accumulate but UDP-Gal will. When dietary
galactose is increased further, it was suggested that the
synthesis of UDP-Glc might become limiting for the
Fig. 2 Case 2, younger sibling with generalized GALE deficiency
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transferase reaction, possibly because of the limited
availability of UTP, and at this point, Gal-1-P and galactose
will begin to accumulate also. The responsibility of the
different accumulating metabolites in the genesis of clinical
manifestations and long-term complications remain unclear.
On the basis of present knowledge, the main objective in
the therapeutic approach of generalized epimerase-deficient
galactosemia seems to be the achievement of a balance
between dietary restriction of galactose to prevent galactose
toxicity and supplying enough galactose for essential
requirements (Henderson et al. 1983, Walter et al. 1999,
Openo et al. 2006, Sarkar et al. 2010, Fridovich-Keil 2013).
However, the galactose intake for optimum outcome
remains unknown, and, as in classical galactosemia, there
is no guarantee that long-term complications will be
completely prevented by this approach (Fridovich-Keil
2013).
In conclusion, the present report expands the clinical
spectrum of GALE deficiency.
Take Home Message
Generalized GALE deficiency (galactosemia type 3) is a
very rare inherited metabolic disease, associated with a
secondary CDG and with a variable clinical spectrum that
can include cardiomyopathy.
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